Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(1 year, 6 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
USRE46276
(Pediatric) | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Apr, 2025
(2 years from now) | |
US8425934 | ASTRAZENECA | Pharmaceutical compositions |
Apr, 2030
(7 years from now) | |
US8425934
(Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Oct, 2030
(7 years from now) | |
US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(12 years from now) | |
US10300065
(Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Nov 5, 2023 |
M (M) | May 9, 2025 |
Pediatric Exclusivity (PED) | Nov 28, 2023 |
Market Authorisation Date: 20 July, 2011
Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; Red...
Dosage: TABLET;ORAL
12
United States
5
China
5
Japan
3
Australia
3
Russia
3
European Union
2
Brazil
2
Malaysia
2
Canada
2
New Zealand
1
Israel
1
South Africa
1
Denmark
1
IB
1
Mexico
1
Saudi Arabia
1
Hong Kong
1
Slovenia
1
Lithuania
1
Hungary
1
Philippines
1
Uruguay
1
Norway
1
Argentina
1
Colombia
1
Croatia
1
Singapore
1
Portugal
1
Sweden
1
Cyprus
1
Spain
1
Korea, Republic of
1
Poland
1
Chile
1
RS
1
Taiwan, Province of China
1
Ukraine
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic